Improving Data Reliability Using a Non-Compliance Detection Method versus Using Pharmacokinetic Criteria
暂无分享,去创建一个
Lewis B. Sheiner | Davide Verotta | Terrence F. Blaschke | T. Blaschke | L. Sheiner | E. Acosta | D. Verotta | Edward P. Acosta | Smita A. Kshirsagar | M. Krygowski | S. Kshirsagar | M. Krygowski
[1] R M Schulz,et al. Patient compliance—an overview , 1992, Journal of clinical pharmacy and therapeutics.
[2] J. Steinberg,et al. Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. , 1998, Archives of pathology & laboratory medicine.
[3] L. Sheiner,et al. Estimating treatment effect in the presence of non‐compliance measured with error: precision and robustness of data analysis methods , 2004, Statistics in medicine.
[4] Marshall Joffe,et al. Causal logistic models for non‐compliance under randomized treatment with univariate binary response , 2003, Statistics in medicine.
[5] Hulin Wu,et al. Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals , 2004, Journal of acquired immune deficiency syndromes.
[6] T. Jarrett,et al. Protease inhibitor-induced urolithiasis. , 1997, Urology.
[7] S. Hammer,et al. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir , 2002, Clinical pharmacology and therapeutics.
[8] K. Miller,et al. Crystalluria and Urinary Tract Abnormalities Associated with Indinavir , 1997, Annals of Internal Medicine.
[9] S. Hammer,et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. , 2003, The Journal of infectious diseases.
[10] P. Reiss,et al. Administration of Indinavir and Low-Dose Ritonavir (800/100 Mg Twice Daily) with Food Reduces Nephrotoxic Peak Plasma Levels of Indinavir , 2002, Antiviral therapy.
[11] T. van der Poll,et al. A Retrospective, Cohort‐Based Survey of Patients Using Twice‐Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy , 2001, Journal of Acquired Immune Deficiency Syndromes.
[12] J. Beijnen,et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. , 1999, AIDS.
[13] Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. , 2001, The Journal of infectious diseases.
[14] C. T. Viswanathan,et al. Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Clinical pharmacology and therapeutics.
[15] J. Dieleman,et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. , 1999, AIDS.
[16] W. Bennett,et al. Renal toxicity of protease inhibitors , 2000, Current opinion in nephrology and hypertension.
[17] C. Solas,et al. High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. , 2002, Journal of acquired immune deficiency syndromes.
[18] Mats O. Karlsson,et al. Use of Prior Information to Stabilize a Population Data Analysis , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[19] M. Karlsson,et al. Discrimination Between Rival Dosing Histories , 1997, Pharmaceutical Research.
[20] Peter L. Anderson,et al. Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir , 2001, Antimicrobial Agents and Chemotherapy.
[21] E. Saltel,et al. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. , 2000, The Journal of urology.
[22] L B Sheiner,et al. Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.
[23] B Vrijens,et al. The impact of compliance in pharmacokinetic studies , 1999, Statistical methods in medical research.
[24] S. Hammer,et al. Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398 , 2003, Antimicrobial Agents and Chemotherapy.
[25] John Urquhart,et al. Role of Patient Compliance in Clinical Pharmacokinetics , 1994 .
[26] A. Telenti,et al. Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus , 2004, Antimicrobial Agents and Chemotherapy.
[27] N M Laird,et al. Correcting for non-compliance in randomized trials: an application to the ATBC Study. , 1999, Statistics in medicine.
[28] J. Miro,et al. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] B. G. Blijenberg,et al. Persistent Leukocyturia and Loss of Renal Function in a Prospectively Monitored Cohort of HIV-Infected Patients Treated with Indinavir , 2003, Journal of acquired immune deficiency syndromes.
[30] Thomas M. Ludden,et al. Estimation of Population Pharmacokinetic Parameters in the Presence of Non-compliance , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[31] L. Sheiner,et al. Selecting Reliable Pharmacokinetic Data for Explanatory Analyses of Clinical Trials in the Presence of Possible Noncompliance , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[32] K. Miller,et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] Tosiya Sato. A method for the analysis of repeated binary outcomes in randomized clinical trials with non‐compliance , 2001, Statistics in medicine.
[34] W. H. Porter,et al. Urolithiasis associated with the protease inhibitor indinavir. , 1997, Urology.
[35] D. Richman,et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine , 2003, AIDS.
[36] M. Resnick,et al. Protease inhibitors and urolithiasis. , 1997, The Journal of urology.
[37] J. Wade,et al. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[38] L. Sheiner,et al. Population one‐compartment pharmacokinetic analysis with missing dosage data , 2004, Clinical pharmacology and therapeutics.
[39] Scott A. Sisson,et al. Transdimensional Markov Chains , 2005 .
[40] E. Acosta,et al. Indinavir Concentrations and Antiviral Effect , 1999, Pharmacotherapy.
[41] B. Stricker,et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. , 2002, Archives of internal medicine.
[42] L B Sheiner,et al. A Markov mixed effect regression model for drug compliance. , 1998, Statistics in medicine.
[43] M. Rowland,et al. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies , 2004, European Journal of Clinical Pharmacology.
[44] C. Tsoukas,et al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[45] D. Richman,et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients , 2000, AIDS.